Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Grundt

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
European Journal of Pharmacology|March 1, 2005
BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonismStephen M Husbands, Claire L Neilan, Jillian Broadbear, et al.
Journal of Medicinal Chemistry|August 4, 2007
Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agentsPeter Grundt, Katherine M Prevatt, Jianjing Cao, et al.
Behavioural Pharmacology|May 14, 2010
Yawning and locomotor behavior induced by dopamine receptor agonists in mice and ratsSu-Min Li, Gregory T Collins, Noel M Paul, et al.
Synapse (New York, N.Y.)|February 1, 2012
Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-dihydro-1H-imidazol-2-yl)-1- methyl-1H-indole), for the imidazoline₂ binding siteRobin J Tyacke, Amy Fisher, Emma S J Robinson, et al.
Molecular Pharmacology|November 6, 2007
Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitorsClaus J Loland, Rajeev I Desai, Mu-Fa Zou, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 13, 2009
Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and miceGregory T Collins, Andrew Truccone, Faiza Haji-Abdi, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
European Journal of Pharmacology|March 1, 2005
BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonismStephen M Husbands, Claire L Neilan, Jillian Broadbear, et al.
Journal of Medicinal Chemistry|August 4, 2007
Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agentsPeter Grundt, Katherine M Prevatt, Jianjing Cao, et al.
Behavioural Pharmacology|May 14, 2010
Yawning and locomotor behavior induced by dopamine receptor agonists in mice and ratsSu-Min Li, Gregory T Collins, Noel M Paul, et al.
Synapse (New York, N.Y.)|February 1, 2012
Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-dihydro-1H-imidazol-2-yl)-1- methyl-1H-indole), for the imidazoline₂ binding siteRobin J Tyacke, Amy Fisher, Emma S J Robinson, et al.
Molecular Pharmacology|November 6, 2007
Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitorsClaus J Loland, Rajeev I Desai, Mu-Fa Zou, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 13, 2009
Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and miceGregory T Collins, Andrew Truccone, Faiza Haji-Abdi, et al.
Pageof 4